Revvity introduces new ivd reference standards for monitoring oncology diagnostic testing workflows

Waltham, mass.--(business wire)--revvity, inc. (nyse: rvty), today announced the launch of three mimix™ reference standards for ivd use, designed for monitoring of next-generation sequencing (ngs) or droplet digital polymerase chain reacting (ddpcr) assays designed to detect somatic mutations in genomic dna (gdna) from human samples for ivd use. these cell line-derived reference standards have undergone appropriate design controls to meet u.s. food and drug administration (fda) regulatory requi.
RVTY Ratings Summary
RVTY Quant Ranking